India’s government is facing stiff resistance from foreign and domestic pharmaceutical companies over its plan to limit prices for drugs severely. This video debates the drug prices in India with a Q&A with Piramal Healthcare CEO, Ajay Piramal.
Source: Wall Street Journal. There may be a short advert at the start.
You must be logged in to post a comment.
The Changing Landscape of the Health Technology Assessment Customer Base
US & UK doing more to decrease health outcomes inequalities
Roche CEO Severin Schwan warns of complete obvious
How Medical Science Liaisons Can Transition to Health Outcomes Liaisons
Co-Dependent Technologies, Market Access and Value Communication
Personalized Medicine in the Age of Health Technology Assessments
Pharma’s Changing Business Model: The Curious Case of Pharmaceutical Price Discrimination
The Escalating Race for Evidence in Drug Reimbursement: Price Versus Value
Francois-Henri: The trend towards outcomes-based reimbursement dec...
Duncan: Very true!...
Doctor and epidemiologist Ben Goldacre shows us, at high speed, the ways evidence can be distorted, from the blindingly obvious nutrition claims to the very subtle tricks of the pharmaceutical industry.
No comments yet.